Impact of everolimus: update on immunosuppressive therapy strategies and patient outcomes after renal transplantation

References

• Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004; 4(3):378–383.
   PubMed Web of Science ®Google Scholar
• Pascual J, Zamora J, Pirsch JD. A systematic review of kidney transplantation from expanded criteria donors. Am J Kidney Dis. 2008; 52(3):553–586.
   Web of Science ®Google Scholar
• Kuypers DR. Immunotherapy in elderly transplant recipients: A guide to clinically significant drug interactions. Drugs Aging. 2009;26(9): 715–737.
   Web of Science ®Google Scholar
• De Bleser L, Matteson M, Dobbels F, Russell C, de Geest S. Interventions to improve medication-adherence after transplantation: A systematic review. Transpl Int. 2009;22(8):780–797.
   Web of Science ®Google Scholar
• Meier-Kriesche HU, Chu AH, David KM, Chi-Burris K, Steffen BJ. Switching immunosuppression medications after renal transplantation – a common practice. Nephrol Dial Transplant. 2006; 21(8):2256–2262.
   Web of Science ®Google Scholar
• Marcen R. Immunosuppressive drugs in kidney transplantation: Impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs. 2009;69(16):2227–2243.
   Web of Science ®Google Scholar
• Grinyo JM, Cruzado JM. Steroid or calcineurin inhibitor-sparing immunosuppressive protocols. Contrib Nephrol. 2005;146:30–42.
   Web of Science ®Google Scholar
• Habwe VQ. Posttransplantation quality of life: More than graft function. Am J Kidney Dis. 2006;47(4 Suppl 2):S98–S110.
   Web of Science ®Google Scholar
• Nickerson P. The impact of immune gene polymorphisms in kidney and liver transplantation. Clin Lab Med. 2008;28(3):455–468, vii.
   Web of Science ®Google Scholar
• Macphee IA. Use of pharmacogenetics to optimize immunosuppressive therapy. Ther Drug Monit. 2010;32(3):261–264.
   PubMed Web of Science ®Google Scholar
• Christians U, Schmitz V, Schoning W, Bendrick-Peart J, Klawitter J, Haschke M. Toxicodynamic therapeutic drug monitoring of immunosuppressants: Promises, reality, and challenges. Ther Drug Monit. 2008; 30(2):151–158.
   PubMed Web of Science ®Google Scholar
• Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124(3):471–484.
   PubMed Web of Science ®Google Scholar
• Neuhaus P, Klupp J, Langrehr JM. mTOR inhibitors: An overview. Liver Transpl. 2001;7(6):473–484.
   PubMed Web of Science ®Google Scholar
• Nashan B. Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs. 2002;11(12):1845–1857.
   PubMed Web of Science ®Google Scholar
• Chapman TM, Perry CM. Everolimus. Drugs. 2004;64(8):861–872.
   Web of Science ®Google Scholar
• Patel JK, Kobashigawa JA. Everolimus: An immunosuppressive agent in transplantation. Expert Opin Pharmacother. 2006;7(10): 1347–1355.
   Google Scholar
• Sanchez-Fructuoso AI. Everolimus: An update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin Drug Metab Toxicol. 2008;4(6):807–819.
   Web of Science ®Google Scholar
• Dunn C, Croom KF Everolimus: A review of its use in renal and cardiac transplantation. Drugs. 2006;66(4):547–570.
   Web of Science ®Google Scholar
• Rostaing L, Kamar N. mTOR inhibitor/proliferation signal inhibitors: Entering or leaving the field? J Nephrol. 2010;23(2):133–142.
   Web of Science ®Google Scholar
• Gabardi S, Baroletti SA. Everolimus: A proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology. Pharmacotherapy. 2010;30(10):1044–1056.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Noe A, Berthier S, et al. Clinical development of an everolimus pediatric formulation: Relative bioavailability, food effect, and steady-state pharmacokinetics. J Clin Pharmacol. 2003;43(2): 141–147.
   PubMed Web of Science ®Google Scholar
• Van Damme-Lombaerts R, Webb NA, Hoyer PF, et al. Single-dose pharmacokinetics and tolerability of everolimus in stable pediatric renal transplant patients. Pediatr Transplant. 2002;6(2):147–152.
   Web of Science ®Google Scholar
• Hoyer PF, Ettenger R, Kovarik JM, et al. Everolimus in pediatric de novo renal transplant patients. Transplantation. 2003;75(12):2082–2085.
   PubMed Web of Science ®Google Scholar
• Ettenger RB, Grimm EM. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients. Am J Kidney Dis. 2001; 38(4 Suppl 2):S22–S28.
   PubMed Web of Science ®Google Scholar
• Ettenger R, Hoyer PF, Grimm P, et al. Multicenter trial of everolimus in pediatric renal transplant recipients: Results at three year. Pediatr Transplant. 2008;12(4):456–463.
   Web of Science ®Google Scholar
• Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo. Transplantation. 1997;64(1):36–42.
   PubMed Web of Science ®Google Scholar
• Struijk GH, Minnee RC, Koch SD, et al. Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses. Kidney Int. 2010;78(9):934–940.
   PubMed Web of Science ®Google Scholar
• Neumayer HH. Introducing everolimus (Certican) in organ transplantation: An overview of preclinical and early clinical developments. Transplantation. 2005;79(Suppl 9):S72–S75.
   Web of Science ®Google Scholar
• Hausen B, Gummert J, Berry GJ, et al. Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: Induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40–0-(2-hydroxyethyl)-rapamycin. Transplantation. 2000;69(4): 488–496.
   Web of Science ®Google Scholar
• Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003;349(9):847–858.
   PubMed Web of Science ®Google Scholar
• Yuan R, Kay A, Berg WJ, Lebwohl D. Targeting tumorigenesis: Development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol. 2009;2:45.
   PubMed Web of Science ®Google Scholar
• Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004;43(2):83–95.
   PubMed Web of Science ®Google Scholar
• Monchaud C, Marquet P. Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: Part II. Clin Pharmacokinet. 2009;48(8):489–516.
   PubMed Web of Science ®Google Scholar
• Serkova N, Hausen B, Berry GJ, et al. Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: Interaction with cyclosporine. J Pharmacol Exp Ther. 2000;294(1): 323–332.
   PubMed Web of Science ®Google Scholar
• Strom T, Haschke M, Zhang YL, et al. Identification of everolimus metabolite patterns in trough blood samples of kidney transplant patients. Ther Drug Monit. 2007;29(5):592–599.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Kahan BD, Kaplan B, et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first posttransplant year: Pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther. 2001;69(1): 48–56.
   Web of Science ®Google Scholar
• Budde K, Fritsche L, Waiser J, Glander P, Slowinski T, Neumayer HH. Pharmacokinetics of the immunosuppressant everolimus in maintenance renal transplant patients. Eur J Med Res. 2005;10(4):169–174.
   Web of Science ®Google Scholar
• Kovarik JM, Kaplan B, Silva HT, et al. Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation. Am J Transplant. 2003;3(5): 606–613.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Hsu CH, McMahon L, Berthier S, Rordorf C. Population pharmacokinetics of everolimus in de novo renal transplant patients: Impact of ethnicity and comedications. Clin Pharmacol Ther. 2001;70(3):247–254.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Sabia HD, Figueiredo J, et al. Influence of hepatic impairment on everolimus pharmacokinetics: Implications for dose adjustment. Clin Pharmacol Ther. 2001;70(5):425^30.
   Web of Science ®Google Scholar
• Kahan BD, Wong RL, Carter C, et al. A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients. Transplantation. 1999;68(8):1100–1106.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Hartmann S, Figueiredo J, et al. Effect of food on everolimus absorption: Quantification in healthy subjects and a confirmatory screening in patients with renal transplants. Pharmacotherapy. 2002; 22(2):154–159.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Beyer D, Schmouder RL. Everolimus drug interactions: Application of a classification system for clinical decision making. Biopharm Drug Dispos. 2006;27(9):421–426.
   Web of Science ®Google Scholar
• Kovarik JM, Kalbag J, Figueiredo J, Rouilly M, Frazier OL, Rordorf C. Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: A clinically relevant pharmacokinetic interaction. J Clin Pharmacol. 2002;42(1):95–99.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Dantal J, Civati G, et al. Influence of delayed initiation of cyclosporine on everolimus pharmacokinetics in de novo renal transplant patients. Am J Transplant. 2003;3(12):1576–1580.
   Web of Science ®Google Scholar
• Kovarik JM, Curtis JJ, Hricik DE, Pescovitz MD, Scantlebury V, Vasquez A. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. Transplant Proc. 2006;38(10): 3456–3458.
   Web of Science ®Google Scholar
• Pascual J, del Castillo D, Cabello M, et al. Interaction between everolimus and tacrolimus in renal transplant recipients: A pharmacokinetic controlled trial. Transplantation. 2010;89(8):994–1000.
   Web of Science ®Google Scholar
• Kovarik JM, Bartlett M, Rordorf C, et al. Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration. Int J Clin Pharmacol Ther. 2010;48(2):103–108.
   Web of Science ®Google Scholar
• Kovarik JM, Tedesco-Silva H, Lien B, et al. Comparative pharmacokinetics of a sotrastaurin-everolimus versus a cyclosporine-everolimus regimen in de novo kidney transplant recipients: 934. Transplantation. 2010;90:252.
   Google Scholar
• Kahan BD, Kaplan B, Lorber MI, Winkler M, Cambon N, Boger RS. RAD in de novo renal transplantation: Comparison of three doses on the incidence and severity of acute rejection. Transplantation. 2001; 71(10):1400–1406.
   PubMed Web of Science ®Google Scholar
• Vitko S, Margreiter R, Weimar W, et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 2005;5(10): 2521–2530.
   PubMed Web of Science ®Google Scholar
• Vitko S, Margreiter R, Weimar W, et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation. 2004;78(10):153–140.
   Web of Science ®Google Scholar
• Lorber MI, Mulgaonkar S, Butt KM, et al. Everolimus versus myco-phenolate mofetil in the prevention of rejection in de novo renal transplant recipients: A 3-year randomized, multicenter, phase III study. Transplantation. 2005;80(2):244–252.
   PubMed Web of Science ®Google Scholar
• Schuurman HJ, Cottens S, Fuchs S, et al. SDZ RAD, a new rapamycin derivative: Synergism with cyclosporine. Transplantation. 1997;64(1):32–35.
   PubMed Web of Science ®Google Scholar
• Kuypers DR. Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring. Ann Transplant. 2008; 13(3):11–18.
   PubMed Web of Science ®Google Scholar
• Serkova NJ, Christians U. Biomarkers for toxicodynamic monitoring of immunosuppressants: NMR-based quantitative metabonomics of the blood. Ther Drug Monit. 2005;27(6):733–737.
   Web of Science ®Google Scholar
• Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP, Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet. 1997;350(9086):1193–1198.
   PubMed Web of Science ®Google Scholar
• Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation. 1999;67(2):276–284.
   PubMed Web of Science ®Google Scholar
• Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: A three-year phase II, randomized, multicenter, open-label study. Transplantation. 2004;78(9):1332–1340.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Tedesco H, Pascual J, et al. Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation. Ther Drug Monit. 2004;26(5):499–505.
   PubMed Web of Science ®Google Scholar
• Keown PA. New concepts in cyclosporine monitoring. Curr Opin NephrolHypertens. 2002;11(6):619–626.
   Web of Science ®Google Scholar
• Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant. 2004;4(4): 626–635.
   PubMed Web of Science ®Google Scholar
• Tedesco-Silva H Jr, Vitko S, Pascual J, et al. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int. 2007;20(1):27–36.
   PubMed Web of Science ®Google Scholar
• Tedesco Silva H Jr, Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure cyclosporine versus mycophenolic acid plus standard-exposure cyclosporine in renal-transplant recipients. Am J Transplant. 2010;10(6):1401–1413.
   PubMed Web of Science ®Google Scholar
• Salvadori M, Scolari MP, Bertoni E, et al. Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: A multicenter, randomized, controlled trial. Transplantation. 2009; 88(10):1194–1202.
   PubMed Web of Science ®Google Scholar
• Dantal J, Berthoux F, Moal MC, et al. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transpl Int. 2010;23(11):1084–1093.
   PubMed Web of Science ®Google Scholar
• Chan L, Greenstein S, Hardy MA, et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation. 2008;85(6): 821–826.
   Web of Science ®Google Scholar
• Chan L, Hartmann E, Cibrik D, Cooper M, Shaw LM. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. Transplantation. 2010;90(1):31–37.
   Web of Science ®Google Scholar
• Hené R, Langer RM, Vitko S, et al. Efficacy benefit with everolimus and very low tacrolimus exposure in de novo renal transplant recipients: 12 month results of the Asset Study: 1549. Transplantation. 2010; 90:109.
   Google Scholar
• Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349(24):2326–2333.
   PubMedGoogle Scholar
• Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitorsparing regimens in solid organ transplantation: Focus on improving renal function and nephrotoxicity. Clin Transplant. 2008;22(1):1–15.
   Web of Science ®Google Scholar
• Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: A systematic review. Drugs. 2007;67(8):1167–1198.
   PubMed Web of Science ®Google Scholar
• Pohanka E. Conversion to everolimus in maintenance patients – current clinical strategies. Nephrol Dial Transplant. 2006;21 Suppl 3: iii24-iii29.
   Web of Science ®Google Scholar
• Ruiz JC, Sanchez-Fructuoso A, Rodrigo E, et al. Conversion to everolimus in kidney transplant recipients: A safe and simple procedure. Transplant Proc. 2006;38(8):2424–2426.
   Web of Science ®Google Scholar
• Sanchez Fructuoso A, Ruiz San Millan JC, Calvo N, et al. Evaluation of the efficacy and safety of the conversion from a calcineurin inhibitor to an everolimus-based therapy in maintenance renal transplant patients. Transplant Proc. 2007;39(7):2148–2150.
   Web of Science ®Google Scholar
• Holdaas H, Bentdal O, Pfeffer P, Mjornstedt L, Solbu D, Midtvedt K. Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: Results of a pilot study. Clin Transplant. 2008;22(3):366–371.
   Web of Science ®Google Scholar
• Giron F, Baez Y, Nino-Murcia A, Rodriguez J, Salcedo S. Conversion therapy to everolimus in renal transplant recipients: Results after one year. Transplant Proc. 2008;40(3):711–713.
   Web of Science ®Google Scholar
• Ayala M, Morales J, Fierro A, Herzog C, Calabran L, Buckel E. Metabolic changes following conversion from an anticalcineurin-based therapy to an everolimus-based one: A single-center experience. Transplant Proc. 2008;40(9):3265–3269.
   Web of Science ®Google Scholar
• Inza A, Balda S, Alvarez E, Zarraga S, Gainza FJ, Lampreabe I. Conversion to everolimus in kidney transplant recipients with decreased renal function. Transplant Proc. 2009;41(6):2134–2136.
   Web of Science ®Google Scholar
• Cataneo-Davila A, Zuniga-Varga J, Correa-Rotter R, Alberu J. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination. Transplant Proc. 2009;41(10):4138–4146.
   PubMed Web of Science ®Google Scholar
• Ruiz JC, Sanchez A, Rengel M, et al. Use of the new proliferation signal inhibitor everolimus in renal transplant patients in Spain: Preliminary results of the EVERODATA registry. Transplant Proc. 2007;39(7):2157–2159.
   Web of Science ®Google Scholar
• Bemelman FJ, de Maar EF, Press RR, et al. Minimization of maintenance immunosuppression early after renal transplantation: An interim analysis. Transplantation. 2009;88(3):421–428.
   Web of Science ®Google Scholar
• Becker T, Arns W, Budde K, et al. Improved renal function of an everolimus/enteric-coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 2 years follow-up of the Zeus Trial: 1757. Transplantation. 2010; 90:109.
   Google Scholar
• Ruiz JC, Fructuoso SA, Hernández D, et al. An appraisal on the convenience of early everolimus introduction and calcineurin inhibitor withdrawal in kidney recipients: the Eric Study: 2165. Transplantation. 2010;90:223.
   Google Scholar
• Pascual J, Fernandez AM, Marcen R, Ortuno J. Conversion to everolimus in a patient with arterial hypertension and recurrent cutaneous neoplasia – a case report. Nephrol Dial Transplant. 2006;21 Suppl 3: iii38-iii41.
   Web of Science ®Google Scholar
• de Fijter JW. Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation. Nephrol Dial Transplant. 2007;22 Suppl 1:i23–i26.
   Google Scholar
• Campistol JM, Schena FP Kaposi’s sarcoma in renal transplant recipients – the impact of proliferation signal inhibitors. Nephrol Dial Transplant. 2007;22 Suppl 1:i17–i22.
   Google Scholar
• Pascual J. Post-transplant lymphoproliferative disorder – the potential of proliferation signal inhibitors. Nephrol Dial Transplant. 2007; 22 Suppl 1:i27–i35.
   Google Scholar
• Chiurchiu C, Carreno CA, Schiavelli R, et al. Results of the conversion to everolimus in renal transplant recipients with posttransplantation malignancies. Transplant Proc. 2010;42(1):277–279.
   Web of Science ®Google Scholar
• Gutierrez-Dalmau A, Campistol JM. The role of proliferation signal inhibitors in post-transplant malignancies. Nephrol Dial Transplant. 2007;22 Suppl 1:i11–i16.
   Google Scholar
• Campistol JM, Albanell J, Arns W, et al. Use of proliferation signal inhibitors in the management of post-transplant malignancies – clinical guidance. Nephrol Dial Transplant. 2007;22 Suppl 1: i36–i41.
   Google Scholar
• Ram R, Swarnalatha G, Neela P Dakshinamurty KV Sirolimus-induced aphthous ulcers which disappeared with conversion to everolimus. Saudi J Kidney Dis Transpl. 2008;19(5):819–820.
   PubMedGoogle Scholar
• Rehm B, Keller F, Mayer J, Stracke S. Resolution of sirolimus-induced pneumonitis after conversion to everolimus. Transplant Proc. 2006;38(3):711–713.
   PubMed Web of Science ®Google Scholar
• Kamar N, Jaafar A, Esposito L, et al. Conversion from sirolimus to everolimus in maintenance renal transplant recipients within a calcineurin inhibitor-free regimen: Results of a 6-month pilot study. Clin Nephrol. 2008;70(2):118–125.
   Web of Science ®Google Scholar
• Lui SL, Chan KW, Tsang R, Yung S, Lai KN, Chan TM. Effect of rapamycin on renal ischemia-reperfusion injury in mice. Transpl Int. 2006;19(10):834–839.
   Web of Science ®Google Scholar
• Lieberthal W, Fuhro R, Andry CC, et al. Rapamycin impairs recovery from acute renal failure: Role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol. 2001;281(4): F693–F706.
   PubMed Web of Science ®Google Scholar
• Durrbach A, Rostaing L, Tricot L, et al. Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor. Transplantation. 2008;85(3): 486–490.
   Web of Science ®Google Scholar
• Stallone G, Di Paolo S, Schena A, et al. Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function. J Am Soc Nephrol. 2004;15(1): 228–233.
   Web of Science ®Google Scholar
• Albano L, Berthoux F, Moal MC, et al. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus. Transplantation. 2009;88(1):69–76.
   PubMed Web of Science ®Google Scholar
• Dean PG, Lund WJ, Larson TS, et al. Wound-healing complications after kidney transplantation: A prospective, randomized comparison of sirolimus and tacrolimus. Transplantation. 2004;77(10): 1555–1561.
   PubMed Web of Science ®Google Scholar
• Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357(25):2562–2575.
   PubMed Web of Science ®Google Scholar
• Margreiter R, Vitko §, Whelchel J, et al. Post-operative tissue regeneration in renal transplantation: Comparable outcome with everolimus or MMF: 538. Transplantation. 2008;86(2S):188.
   Google Scholar
• Letavernier E, Legendre C. mToR inhibitors-induced proteinuria: Mechanisms, significance, and management. Transplant Rev (Orlando). 2008;22(2):125–130.
   Google Scholar
• Biancone L, Bussolati B, Mazzucco G, et al. Loss of nephrin expression in glomeruli of kidney-transplanted patients under mTOR inhibitor therapy. Am J Transplant. 2010;10(10): 2270–2278.
   Web of Science ®Google Scholar
• Badiou S, Cristol JP, Mourad G. Dyslipidemia following kidney transplantation: Diagnosis and treatment. Curr Diab Rep. 2009;9(4): 305–311.
   Web of Science ®Google Scholar
• Kasiske BL, de Mattos A, Flechner SM, et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant. 2008;8(7):1384–1392.
   PubMed Web of Science ®Google Scholar
• Balla A, Chobanian M. New-onset diabetes after transplantation: A review of recent literature. Curr Opin Organ Transplant. 2009;14(4):375–379.
   PubMed Web of Science ®Google Scholar
• Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol. 2008;19(7):1411–1418.
   PubMed Web of Science ®Google Scholar
• Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant. 2005;5(2):218–227.
   PubMed Web of Science ®Google Scholar
• Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. Transplantation. 2006;81(9): 1234–1248.
   PubMed Web of Science ®Google Scholar
• Fortun J, Martin-Davila P, Pascual J, et al. Immunosuppressive therapy and infection after kidney transplantation. Transpl Infect Dis. 2010;12(5):397^05.
   Web of Science ®Google Scholar
• Kim YS, Tedesco-Silva H, Johnston T, et al. Lower incidence of cytomegalovirus and BK virus with everolimus versus mycophenolate in de novo renal transplant patients: Results from a multicenter, prospective study: 1615. Transplantation. 2010;90:256.
   Google Scholar
• Ramos E, Drachenberg CB, Wali R, Hirsch HH. The decade of polyomavirus BK-associated nephropathy: State of affairs. Transplantation. 2009;87(5):621–630.
   PubMed Web of Science ®Google Scholar
• Fortin MC, Raymond MA, Madore F, et al. Increased risk of thrombotic microangiopathy in patients receiving a cyclosporine-sirolimus combination. Am J Transplant. 2004;4(6):946–952.
   Web of Science ®Google Scholar
• Reynolds JC, Agodoa LY, Yuan CM, Abbott KC. Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis. 2003;42(5):1058–1068.
   PubMed Web of Science ®Google Scholar
• Sartelet H, Toupance O, Lorenzato M, et al. Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transplant. 2005;5(10):2441–2447.
   Web of Science ®Google Scholar
• Ponticelli C. De novo thrombotic microangiopathy. An underrated complication of renal transplantation. Clin Nephrol. 2007;67(6): 335–340.
   Web of Science ®Google Scholar
• Robson M, Cote I, Abbs I, Koffman G, Goldsmith D. Thrombotic microangiopathy with sirolimus-based immunosuppression: Potentiation of calcineurin-inhibitor-induced endothelial damage? Am J Transplant. 2003;3(3):324–327.
   PubMed Web of Science ®Google Scholar
• Stevens B, Flechner S, Wei LJ, et al. Similar risk of renal graft loss due to thrombosis for everolimus versus MPA-based regimens: 1875. Transplantation. 2010;90:439.
   Google Scholar
• Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol. 2006;17(2):581–589.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Moreno A, Ridao N, Garcia-Ledesma P, et al. Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: Experience in a center. Transplant Proc. 2009;41(6): 2163–2165.
   PubMed Web of Science ®Google Scholar
• Chan L, Cibrik D, Johnston T, et al. Correlation of everolimus exposure with efficacy and safety outcomes: Results from a multicenter study in renal transplantation using reduced CsA exposure: 2027. Transplantation. 2010;90:111.
   Google Scholar
• Vathsala A, Zibari G, Kim YS, et al. Dose related incidences of wound healing events in renal transplant recipients treated with everolimus and cyclosporine: 2060. Transplantation. 2010;90:615.
   Google Scholar
• Mabasa VH, Ensom MH. The role of therapeutic monitoring of everolimus in solid organ transplantation. Ther Drug Monit. 2005;27(5): 666–676.
   PubMed Web of Science ®Google Scholar
• Korecka M, Shaw LM. Review of the newest HPLC methods with mass spectrometry detection for determination of immunosuppressive drugs in clinical practice. Ann Transplant. 2009;14(2):61–72.
   PubMed Web of Science ®Google Scholar
• Salm P, Warnholtz C, Boyd J, Arabshahi L, Marbach P, Taylor PJ. Evaluation of a fluorescent polarization immunoassay for whole blood everolimus determination using samples from renal transplant recipients. Clin Biochem. 2006;39(7):732–738.
   Web of Science ®Google Scholar
• Moes DJ, Press RR, de Fijter JW, Guchelaar HJ, den Hartigh J. Liquid chromatography-tandem mass spectrometry outperforms fluorescence polarization immunoassay in monitoring everolimus therapy in renal transplantation. Ther Drug Monit. 2010;32(4):413^419.
   Web of Science ®Google Scholar
• Podder H, Podbielski J, Hussein I, Katz S, van Buren C, Kahan BD. Sirolimus improves the two-year outcome of renal allografts in African-American patients. Transpl Int. 2001;14(3):135–142.
   PubMed Web of Science ®Google Scholar
• Neylan JF. Immunosuppressive therapy in high-risk transplant patients: Dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 1997;64(9): 1277–1282.
   Web of Science ®Google Scholar
• Geissler EK, Schlitt HJ. The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation. Kidney Int. 2010;78(11):1075–1079.
   Web of Science ®Google Scholar
• Cravedi P, Ruggenenti P, Remuzzi G. Sirolimus for calcineurin inhibitors in organ transplantation: Contra. Kidney Int. 2010;78(11): 1068–1074.
   PubMed Web of Science ®Google Scholar